Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
== R == r-selection – radiobiology – receptor (biochemistry) – receptor (immunology) – recombination – Red Queen – redox reaction – redox system – reduction – reflex – Renal corpuscle – repeats – replication bubble – repressor – reproduction – reproductive system – respiration (physiology) – restriction enzyme – retrovirus – reverse genetics – RFLP – Rh blood group system – ribosome – RNA – RNA virus – Robert Koch – root – rough ER – RuBP – Rudolf Steiner –
A common example of backpressure is that caused by the exhaust system (consisting of the exhaust manifold, catalytic converter, muffler and connecting pipes) of an automotive four-stroke engine, which has a negative effect on engine efficiency, resulting in a decrease of power output that must be compensated by increasing fuel consumption. In a piston-ported two-stroke engine, however, the situation is more complicated, due to the need to prevent unburned fuel/air mixture from passing right through the cylinders into the exhaust. During the exhaust phase of the cycle, backpressure is even more undesirable than in a four-stroke engine, as there is less time available for exhaust and the lack of pumping action from the piston to force the exhaust out of the cylinder. However, since the exhaust port necessarily remains open for a time after scavenging is completed, unburned mixture can follow the exhaust out of the cylinder, wasting fuel and increasing pollution. This can only be prevented if the pressure at the exhaust port is greater than that in the cylinder. Since the timing of this process is determined mainly by exhaust system geometry, which is extremely difficult to make variable, correct timing and therefore optimum engine efficiency can typically only be achieved over a small part of the engine's range of operating speed.
Large-scale digitization programmes have made fungarium metadata increasingly available for research and public access. Digitization involves transcribing specimen information into structured databases, commonly following the Darwin Core standard maintained by the Biodiversity Information Standards community to support the sharing of biodiversity information. Electronic specimen catalogues increase the usefulness of fungaria by allowing specimens to be queried by attributes such as locality, habitat, morphology, and collector, and they can help identify taxonomic or geographic gaps in the holdings. Databasing fungarium specimens can also reveal discrepancies between literature-based inventories and voucher-backed collections, helping to show where reported diversity is not yet adequately supported by preserved material. Analysis of databased holdings may in turn guide strategic collecting by identifying underrepresented taxa and geographic areas in existing collections. Digitization may also involve retrospective georeferencing, in which textual locality descriptions on older specimen labels are translated into coordinates so that records can be mapped and analysed more effectively. The Global Biodiversity Information Facility (GBIF) is a global aggregator that uses Darwin Core Archives as a common format for publishing and distributing occurrence datasets derived from specimens and observations.
In December 2005, Eli Lilly and Company pleaded guilty and paid $36 million in connection with the illegal promotion of Raloxifene (Evista), a medication typically used to prevent and treat osteoporosis in postmenopausal women. Sales representatives were trained to promote Evista for breast cancer and cardiovascular disease, to prompt or bait questions from doctors, and to send them unsolicited letters promoting Evista for unapproved use. The company also distributed a videotape in which a sales representative declared that "Evista truly is the best drug for the prevention of all these diseases." Some sales representatives had also been instructed to conceal the disclosure page which stated that the effectiveness of the drug in reducing breast cancer risks had not yet been established.
Sources: en.wikipedia.org
== Pharmacology == As with other nonsteroidal anti-inflammatory drugs, the primary mechanism responsible for its anti-inflammatory, antipyretic and analgesic action is thought to be inhibition of prostaglandin synthesis through COX-inhibition. The main target in the inhibition of prostaglandin synthesis appears to be the transiently expressed prostaglandin-endoperoxide synthase-2 (PGES-2), also known as cycloxygenase-2 (COX-2). That is, diclofenac is partially selective for COX-2. The reported selectivity for COX-2 varies from 1.5 to 30 depending on the source. The drug may be bacteriostatic via inhibiting bacterial DNA synthesis. Diclofenac has a relatively high lipid solubility, making it one of the few nonsteroidal anti-inflammatory drugs that are able to enter the brain by crossing the blood-brain barrier. As in the rest of the body, it is thought to exert its effect in the brain through inhibition of COX-2. In addition, it may have effects inside the spinal cord. Diclofenac may be a unique member of the nonsteroidal anti-inflammatory drugs in other aspects. Some evidence indicates it inhibits the lipoxygenase pathways, thus reducing the formation of leukotrienes (also pro-inflammatory autacoids). It also may inhibit phospholipase A2, which may be relevant to its mechanism of action. These additional actions may explain its high potency –it is the most potent NSAID on a broad basis. Marked differences exist among nonsteroidal anti-inflammatory drugs in their selective inhibition of the two subtypes of cyclooxygenase, COX-1, and COX-2.
an aromatic aldehyde + NADH + H+ The two substrates of this enzyme are an aromatic alcohol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are the corresponding aromatic aldehyde, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is aryl-alcohol:NAD+ oxidoreductase. Other names in common use include p-hydroxybenzyl alcohol dehydrogenase, benzyl alcohol dehydrogenase, and coniferyl alcohol dehydrogenase. This enzyme participates in 5 metabolic pathways: tyrosine metabolism, phenylalanine metabolism, biphenyl degradation, toluene and xylene degradation, and caprolactam degradation.
=== Molecular biology === In 2023, researchers at the University of California, San Francisco presented Thagomizer, a modality for the interrogation of RNA-protein binding events in CLIP-Seq (Cross-linking and immunoprecipitation) data.
== Adverse effects == Most of the comparatively few fatal incidents associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially alcohol. A common adverse effect resulting from psilocybin mushroom use involves "bad trips" or panic reactions, in which people become anxious, confused, agitated, or disoriented. Accidents, self-injury, or suicide attempts can result from serious cases of acute psychotic episodes. No studies have linked psilocybin with birth defects, but it is recommended that pregnant women avoid its usage.
== Life and education == Born in Chattanooga, Tennessee (April 5, 1970), Sherrill received his S.B. in chemistry from MIT. He received his Ph.D. in 1996 from the University of Georgia, working with Professor Henry F. Schefer, III on highly correlated configuration interaction methods. He was an NSF Postdoctoral Fellow in the laboratory of Martin Head-Gordon at the University of California, Berkeley.
Sources: en.wikipedia.org
==== Volumetric analysis ==== Titration involves the gradual addition of a measurable reactant to an exact volume of a solution being analyzed until some equivalence point is reached. Titration is a family of techniques used to determine the concentration of an analyte. Titrating accurately to either the half-equivalence point or the endpoint of a titration allows the chemist to determine the amount of moles used, which can then be used to determine a concentration or composition of the titrant. Most familiar to those who have taken chemistry during secondary education is the acid-base titration involving a color-changing pH indicator, such as phenolphthalein. There are many other types of titrations, including potentiometric titrations and precipitation titrations. Chemists might also create titration curves by systematically testing the pH after every added drop in order to understand different properties of the titrant.
== Controversy == During the negotiations to buy Vasco, Brazilian newspaper O Globo revealed that Wander had been convicted in 2004 for ordering cocaine in the mail while a 22-year-old student of the University of Florida. Facing a possible 26-year sentence, he pleaded no contest and received 15 years of probation, that ended in 2018. Wander's conviction has been brought up in the media, and in an interview with the Financial Times he called it a "stupid college thing" and a "perfect opportunity for those people that are haters to try to destroy you with things that are somewhat meaningless". Norwegian football investigation website Josimar wrote in 2023 that 777 was facing allegations of financial impropriety, including fraud and unpaid bills. 777 condemned Josimar's article as "wholly misleading". 777 Partners have been sued by multiple organizations for unpaid debts and contract breaches with lawsuits describing their financial practices as a "house of cards" and a "sprawling fraudulent enterprise". In May 2024, American insurance firm Advantage Capital Holdings LLC (A-CAP), a major investor in 777 Partners, hired Moelis & Company to review 777's portfolio. A-CAP's loans had been secured against 777's assets. In July, A-CAP wrote to 777 Partners' soccer clubs to inform them that it was the new owner. In October 2024, 777's UK entity was declared bankrupt by the High Court. In August 2025, Delaware judge Christian Douglas Wright put 777 Partners into limited receivership over unpaid legal bills of nearly $600,000 for former CFO Damien Alfalla.
Fibrinogen (coagulation factor I) is a glycoprotein complex, produced in the liver, that circulates in the blood of all vertebrates. During tissue and vascular injury, it is converted enzymatically by thrombin to fibrin and then to a fibrin-based blood clot. Fibrin clots function primarily to occlude blood vessels to stop bleeding. Fibrin also binds and reduces the activity of thrombin. This activity, sometimes referred to as antithrombin I, limits clotting. Fibrin also mediates blood platelet and endothelial cell spreading, tissue fibroblast proliferation, capillary tube formation, and angiogenesis and thereby promotes revascularization and wound healing. Reduced and/or dysfunctional fibrinogens occur in various congenital and acquired human fibrinogen-related disorders. These disorders represent a group of rare conditions in which individuals may present with severe episodes of pathological bleeding and thrombosis; these conditions are treated by supplementing blood fibrinogen levels and inhibiting blood clotting, respectively. These disorders may also be the cause of certain liver and kidney diseases. Fibrinogen is a "positive" acute-phase protein, i.e. its blood levels rise in response to systemic inflammation, tissue injury, and certain other events. It is also elevated in various cancers. Elevated levels of fibrinogen in inflammation as well as cancer and other conditions have been suggested to be the cause of thrombosis and vascular injury that accompanies these conditions.
Side-door vessels have water-tight ports on the ship's hull, which open into a cargo hold. Elevators or ramps leading from the quay serve as loading and discharging access for the forklifts or conveyors. Inside these access ports or side doors, pallet lifts or another series of conveyors bring the cargo to the respective decks. This special design makes the vessels particularly well suited for inclement weather operations as the tops of the cargo holds are always closed against rain and sun. Conventional vessels have a traditional cargo operation with top opening hatches and cranes/derricks. On such ships, when facing wet weather, the hatches need to be closed to prevent heavy rain from flooding the holds. Both above ship types are well suited for the handling of palletized and loose cargo. Refrigerated container ships are specifically designed to carry containerised unit loads where each container has its individual refrigerated unit. These containers are nearly always twenty-foot equivalent units (often called TEU) that are the size of "standard" cargo containers that are loaded and unloaded at container terminals and aboard container ships. These ships differ from conventional container ships in their design, power generation, and electrical distribution equipment. They need provisions made for powering each container's cooling system. Because of their ease of loading and unloading cargo many container ships are now being built or redesigned to carry refrigerated containers.
Mob Life: Gangster Kings of Crime – slideshow by Life magazine UNODC – United Nations Office on Drugs and Crime – sub-section dealing with organized crime worldwide "Organized Crime" – Oxford Bibliographies Online: Criminology. Archived 2010-04-25 at the Wayback Machine
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.